Add Yahoo as a preferred source to see more of our stories on Google. Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for ...

A twice-a-year injectable drug has been shown to be 100% effective in preventing the spread of HIV, according to the first data from a clinical trial. If approved, the drug offers another preventive ...

It’s been over a decade since the Food and Drug Administration first approved a medication to prevent HIV. But the Centers for Disease Control and Prevention estimates just 30% of the 1.2 million ...

The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

ATLANTA — Five years ago, the U.S. government unveiled a plan to end the HIV epidemic by 2030. More than 30,000 people are diagnosed with HIV every year in this country. But this is not a problem for ...

HIV rates are up in Atlanta. Activists and Georgia politicians say this doesn’t have to happen because cheap and safe medicines known as PrEP are over 99% effective at blocking the infection when ...

In June, Gilead Sciences announced impressive early results from its PURPOSE 1 trial, which showed 100 percent efficacy of lenacapavir in preventing new HIV infections among cisgender women in ...

It’s possible to produce a generic version of lenacapavir, a twice-yearly antiretroviral injection that both prevents and treats HIV, for as little as $25 per patient per year, according to a study ...

After nearly a decade of working as an advocate for HIV and AIDS treatment, Michael Chancley said he came to a sobering realization. “Seeing that people who look like me, who hang out at the same ...

Cullen Smith takes an HIV preventative medication every day for “added security” and “peace of mind” after he thought he may have contracted the disease from a partner last year. “Once that situation ...

India introduced PrEP guidelines in 2022, but access remains limited due to lack of public rollout, low awareness, and high costs. Meanwhile, HIV prevalence has declined overall but remains ...